Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing

Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2012-11, Vol.7 (11), p.e50366-e50366
Main Authors: Elshabrawy, Hatem A, Coughlin, Melissa M, Baker, Susan C, Prabhakar, Bellur S
Format: Article
Language:English
Subjects:
Amino acids
Antibodies, Neutralizing - pharmacology
Antibodies, Viral - pharmacology
Antibody Affinity
Antibody Specificity
Binding
Binding Sites, Antibody
Biology
Cell growth
Clinical isolates
Cloning
Cross Reactions
Epitope Mapping
Glycoproteins
Health aspects
HEK293 Cells
Humans
Immune serum
Immunoglobulins
Immunology
Immunotherapy
Infections
Laboratories
Medicine
Membrane Glycoproteins - antagonists & inhibitors
Membrane Glycoproteins - genetics
Membrane Glycoproteins - immunology
Monoclonal antibodies
Mutagenesis
Neutralization Tests
Neutralizing
Patients
Plasmids
Protein Binding
Protein Structure, Tertiary
Proteins
Recombinant Proteins - antagonists & inhibitors
Recombinant Proteins - genetics
Recombinant Proteins - immunology
SARS Virus - drug effects
SARS Virus - genetics
SARS Virus - immunology
Severe acute respiratory syndrome
Severe Acute Respiratory Syndrome - immunology
Severe Acute Respiratory Syndrome - prevention & control
Spike Glycoprotein, Coronavirus
Spike protein
Transfection
Vaccines
Viral Envelope Proteins - antagonists & inhibitors
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3
cites cdi_FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3
container_end_page e50366
container_issue 11
container_start_page e50366
container_title PloS one
container_volume 7
creator Elshabrawy, Hatem A
Coughlin, Melissa M
Baker, Susan C
Prabhakar, Bellur S
description Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.
doi_str_mv 10.1371/journal.pone.0050366
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1326749386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477052406</galeid><doaj_id>oai_doaj_org_article_67b51cb95ef04534b77a318debdaa6e8</doaj_id><sourcerecordid>A477052406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3</originalsourceid><addsrcrecordid>eNqNk1FrFDEQxxdRbK1-A9GAIPpwZ7LZZG9fhONQWygUWu1rmE1m91J3kzPZLdZnP7hZey130gcJbJbkN__J_JPJspeMzhkv2YcrPwYH3XzjHc4pFZRL-Sg7ZBXPZzKn_PHO_0H2LMarBPGFlE-zg5yzhZC0Osx-H489ONJ753Xnkx4BN9jaG4uRQAvWxYGsbbvuboj2LmK4RkOOz1nipjknxvcTRXxDhjWSi-X5xWzlL0nc2O9INsEPaB2BgClJ-tTBg0liDschQGd_Wdc-z5400EV8sZ2Psm-fP31dHc9Oz76crJanM12KxTDjJWVNDlQXGgxFIxssQRRgDAgpK8GqRUHzoqgqzgwzvMmZEDyvy0obbRjwo-z1re6m81FtDYyK8VyWRZW8ScTJLWE8XKlNsD2EG-XBqr8LPrQKwmB1h0qWtWC6rgQ2tBC8qMsSkq0GawMgcZG0Pm6zjXWPRqObCt4T3d9xdq1af614ustKTod5txUI_seIcVC9jRq7Dhz6MZ07z6koKa14Qt_8gz5c3ZZqIRVgXeNTXj2JqmVRllTkBZ2o-QNUGgZ7m94ANjat7wW83wtIzIA_hxbGGNXJxfn_s2eX--zbHXaN0A3r6LtxsOkh7oPFLaiDjzFgc28yo2pqljs31NQsatssKezV7gXdB911B_8DcjsPdw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1326749386</pqid></control><display><type>article</type><title>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Elshabrawy, Hatem A ; Coughlin, Melissa M ; Baker, Susan C ; Prabhakar, Bellur S</creator><contributor>Pyrc, Krzysztof</contributor><creatorcontrib>Elshabrawy, Hatem A ; Coughlin, Melissa M ; Baker, Susan C ; Prabhakar, Bellur S ; Pyrc, Krzysztof</creatorcontrib><description>Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0050366</identifier><identifier>PMID: 23185609</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Amino acids ; Antibodies, Neutralizing - pharmacology ; Antibodies, Viral - pharmacology ; Antibody Affinity ; Antibody Specificity ; Binding ; Binding Sites, Antibody ; Biology ; Cell growth ; Clinical isolates ; Cloning ; Cross Reactions ; Epitope Mapping ; Glycoproteins ; Health aspects ; HEK293 Cells ; Humans ; Immune serum ; Immunoglobulins ; Immunology ; Immunotherapy ; Infections ; Laboratories ; Medicine ; Membrane Glycoproteins - antagonists &amp; inhibitors ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - immunology ; Monoclonal antibodies ; Mutagenesis ; Neutralization Tests ; Neutralizing ; Patients ; Plasmids ; Protein Binding ; Protein Structure, Tertiary ; Proteins ; Recombinant Proteins - antagonists &amp; inhibitors ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; SARS Virus - drug effects ; SARS Virus - genetics ; SARS Virus - immunology ; Severe acute respiratory syndrome ; Severe Acute Respiratory Syndrome - immunology ; Severe Acute Respiratory Syndrome - prevention &amp; control ; Spike Glycoprotein, Coronavirus ; Spike protein ; Transfection ; Vaccines ; Viral Envelope Proteins - antagonists &amp; inhibitors ; Viral Envelope Proteins - genetics ; Viral Envelope Proteins - immunology ; Viruses</subject><ispartof>PloS one, 2012-11, Vol.7 (11), p.e50366-e50366</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Elshabrawy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2012 Elshabrawy et al 2012 Elshabrawy et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3</citedby><cites>FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1326749386/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1326749386?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23185609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Pyrc, Krzysztof</contributor><creatorcontrib>Elshabrawy, Hatem A</creatorcontrib><creatorcontrib>Coughlin, Melissa M</creatorcontrib><creatorcontrib>Baker, Susan C</creatorcontrib><creatorcontrib>Prabhakar, Bellur S</creatorcontrib><title>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.</description><subject>Amino acids</subject><subject>Antibodies, Neutralizing - pharmacology</subject><subject>Antibodies, Viral - pharmacology</subject><subject>Antibody Affinity</subject><subject>Antibody Specificity</subject><subject>Binding</subject><subject>Binding Sites, Antibody</subject><subject>Biology</subject><subject>Cell growth</subject><subject>Clinical isolates</subject><subject>Cloning</subject><subject>Cross Reactions</subject><subject>Epitope Mapping</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Immune serum</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Medicine</subject><subject>Membrane Glycoproteins - antagonists &amp; inhibitors</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Monoclonal antibodies</subject><subject>Mutagenesis</subject><subject>Neutralization Tests</subject><subject>Neutralizing</subject><subject>Patients</subject><subject>Plasmids</subject><subject>Protein Binding</subject><subject>Protein Structure, Tertiary</subject><subject>Proteins</subject><subject>Recombinant Proteins - antagonists &amp; inhibitors</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>SARS Virus - drug effects</subject><subject>SARS Virus - genetics</subject><subject>SARS Virus - immunology</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe Acute Respiratory Syndrome - immunology</subject><subject>Severe Acute Respiratory Syndrome - prevention &amp; control</subject><subject>Spike Glycoprotein, Coronavirus</subject><subject>Spike protein</subject><subject>Transfection</subject><subject>Vaccines</subject><subject>Viral Envelope Proteins - antagonists &amp; inhibitors</subject><subject>Viral Envelope Proteins - genetics</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1FrFDEQxxdRbK1-A9GAIPpwZ7LZZG9fhONQWygUWu1rmE1m91J3kzPZLdZnP7hZey130gcJbJbkN__J_JPJspeMzhkv2YcrPwYH3XzjHc4pFZRL-Sg7ZBXPZzKn_PHO_0H2LMarBPGFlE-zg5yzhZC0Osx-H489ONJ753Xnkx4BN9jaG4uRQAvWxYGsbbvuboj2LmK4RkOOz1nipjknxvcTRXxDhjWSi-X5xWzlL0nc2O9INsEPaB2BgClJ-tTBg0liDschQGd_Wdc-z5400EV8sZ2Psm-fP31dHc9Oz76crJanM12KxTDjJWVNDlQXGgxFIxssQRRgDAgpK8GqRUHzoqgqzgwzvMmZEDyvy0obbRjwo-z1re6m81FtDYyK8VyWRZW8ScTJLWE8XKlNsD2EG-XBqr8LPrQKwmB1h0qWtWC6rgQ2tBC8qMsSkq0GawMgcZG0Pm6zjXWPRqObCt4T3d9xdq1af614ustKTod5txUI_seIcVC9jRq7Dhz6MZ07z6koKa14Qt_8gz5c3ZZqIRVgXeNTXj2JqmVRllTkBZ2o-QNUGgZ7m94ANjat7wW83wtIzIA_hxbGGNXJxfn_s2eX--zbHXaN0A3r6LtxsOkh7oPFLaiDjzFgc28yo2pqljs31NQsatssKezV7gXdB911B_8DcjsPdw</recordid><startdate>20121121</startdate><enddate>20121121</enddate><creator>Elshabrawy, Hatem A</creator><creator>Coughlin, Melissa M</creator><creator>Baker, Susan C</creator><creator>Prabhakar, Bellur S</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20121121</creationdate><title>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</title><author>Elshabrawy, Hatem A ; Coughlin, Melissa M ; Baker, Susan C ; Prabhakar, Bellur S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Amino acids</topic><topic>Antibodies, Neutralizing - pharmacology</topic><topic>Antibodies, Viral - pharmacology</topic><topic>Antibody Affinity</topic><topic>Antibody Specificity</topic><topic>Binding</topic><topic>Binding Sites, Antibody</topic><topic>Biology</topic><topic>Cell growth</topic><topic>Clinical isolates</topic><topic>Cloning</topic><topic>Cross Reactions</topic><topic>Epitope Mapping</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Immune serum</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Medicine</topic><topic>Membrane Glycoproteins - antagonists &amp; inhibitors</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Monoclonal antibodies</topic><topic>Mutagenesis</topic><topic>Neutralization Tests</topic><topic>Neutralizing</topic><topic>Patients</topic><topic>Plasmids</topic><topic>Protein Binding</topic><topic>Protein Structure, Tertiary</topic><topic>Proteins</topic><topic>Recombinant Proteins - antagonists &amp; inhibitors</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>SARS Virus - drug effects</topic><topic>SARS Virus - genetics</topic><topic>SARS Virus - immunology</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe Acute Respiratory Syndrome - immunology</topic><topic>Severe Acute Respiratory Syndrome - prevention &amp; control</topic><topic>Spike Glycoprotein, Coronavirus</topic><topic>Spike protein</topic><topic>Transfection</topic><topic>Vaccines</topic><topic>Viral Envelope Proteins - antagonists &amp; inhibitors</topic><topic>Viral Envelope Proteins - genetics</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elshabrawy, Hatem A</creatorcontrib><creatorcontrib>Coughlin, Melissa M</creatorcontrib><creatorcontrib>Baker, Susan C</creatorcontrib><creatorcontrib>Prabhakar, Bellur S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elshabrawy, Hatem A</au><au>Coughlin, Melissa M</au><au>Baker, Susan C</au><au>Prabhakar, Bellur S</au><au>Pyrc, Krzysztof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-11-21</date><risdate>2012</risdate><volume>7</volume><issue>11</issue><spage>e50366</spage><epage>e50366</epage><pages>e50366-e50366</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23185609</pmid><doi>10.1371/journal.pone.0050366</doi><tpages>e50366</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2012-11, Vol.7 (11), p.e50366-e50366
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1326749386
source Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database
subjects Amino acids
Antibodies, Neutralizing - pharmacology
Antibodies, Viral - pharmacology
Antibody Affinity
Antibody Specificity
Binding
Binding Sites, Antibody
Biology
Cell growth
Clinical isolates
Cloning
Cross Reactions
Epitope Mapping
Glycoproteins
Health aspects
HEK293 Cells
Humans
Immune serum
Immunoglobulins
Immunology
Immunotherapy
Infections
Laboratories
Medicine
Membrane Glycoproteins - antagonists & inhibitors
Membrane Glycoproteins - genetics
Membrane Glycoproteins - immunology
Monoclonal antibodies
Mutagenesis
Neutralization Tests
Neutralizing
Patients
Plasmids
Protein Binding
Protein Structure, Tertiary
Proteins
Recombinant Proteins - antagonists & inhibitors
Recombinant Proteins - genetics
Recombinant Proteins - immunology
SARS Virus - drug effects
SARS Virus - genetics
SARS Virus - immunology
Severe acute respiratory syndrome
Severe Acute Respiratory Syndrome - immunology
Severe Acute Respiratory Syndrome - prevention & control
Spike Glycoprotein, Coronavirus
Spike protein
Transfection
Vaccines
Viral Envelope Proteins - antagonists & inhibitors
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viruses
title Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20monoclonal%20antibodies%20against%20highly%20conserved%20HR1%20and%20HR2%20domains%20of%20the%20SARS-CoV%20spike%20protein%20are%20more%20broadly%20neutralizing&rft.jtitle=PloS%20one&rft.au=Elshabrawy,%20Hatem%20A&rft.date=2012-11-21&rft.volume=7&rft.issue=11&rft.spage=e50366&rft.epage=e50366&rft.pages=e50366-e50366&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0050366&rft_dat=%3Cgale_plos_%3EA477052406%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c758t-3701f2a0c4cad0ed6fe7a54adda56695198402449931d1d3f215532b79cdcd1a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1326749386&rft_id=info:pmid/23185609&rft_galeid=A477052406&rfr_iscdi=true